MorphoSys AG announced that its lawsuit against Janssen Biotech and Genmab A/S has been settled. The parties have agreed to drop the mutual claims related to this litigation.

MorphoSys filed a lawsuit in the U.S. District Court of Delaware against Janssen Biotech, and Genmab, A/S in 2016 for patent infringement, and again In 2017, for a second and a third patent. MorphoSys sought reperations for alleged infringement by Janssen’s and Genmab’s daratumumab, a monoclonal antibody for the treatment of multiple myeloma.

MorphoSys is dismissing the claims and did not appeal in the previously-announced court order. Janssen and Genmab are dismissing their counterclaims.

Subscribe To Our Newsletter

Would you like to receive our popular weekly news alerts straight to your inbox? Solely patent focused and only sent once a week means you can guarantee there will be something you are interested in reading instead of clogging up your inbox with junk. Sign up now!

You have Successfully Subscribed!